H. Arem, S. C. Moore, A. Patel, P. Hartge, A. Berrington-de-gonzalez et al., Leisure 441 time physical activity and mortality: a detailed pooled analysis of the dose-response 442 relationship, JAMA Intern Med, vol.175, pp.959-967, 2015.

H. H. Kyu, V. F. Bachman, L. T. Alexander, J. E. Mumford, A. Afshin et al., Physical activity and 444 risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke 445 events: systematic review and dose-response meta-analysis for the Global Burden of Disease 446 Study, BMJ, vol.354, p.3857, 2013.

A. F. Yu and L. W. Jones, Breast cancer treatment-associated cardiovascular toxicity and effects of 448 exercise countermeasures, Cardio-Oncol Lond Engl, vol.2, 2016.

S. M. Swain, F. S. Whaley, and M. S. Ewer, Congestive heart failure in patients treated with doxorubicin: a 450 retrospective analysis of three trials, Cancer, vol.97, pp.2869-2879, 2003.

L. A. Smith, V. R. Cornelius, C. J. Plummer, G. Levitt, M. Verrill et al., Cardiotoxicity of 452 anthracycline agents for the treatment of cancer: systematic review and meta-analysis of 453 randomised controlled trials, BMC Cancer, vol.10, p.337, 2010.

S. Mantarro, M. Rossi, M. Bonifazi, D. 'amico, R. Blandizzi et al., Risk of severe 455 cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort 456 studies of 29,000 women with breast cancer, Intern Emerg Med, vol.11, pp.123-140, 2016.

T. Chen, T. Xu, Y. Li, C. Liang, J. Chen et al., Risk of cardiac dysfunction with trastuzumab in 458 breast cancer patients: a meta-analysis, Cancer Treat Rev, vol.37, pp.312-320, 2011.

I. Smith, M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova et al., 2-year follow-up 460 of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised 461 controlled trial, Lancet Lond Engl, vol.369, pp.29-36, 2007.

Z. Luis, L. Patrizio, and R. Daniel, Asteggiano, vol.463

G. Riccardo and . Maurizio, ESC Position Paper on cancer treatments and 464 cardiovascular toxicity developed under the auspices of the ESC Committee for Practice 465 Guidelines, Eur J Heart Fail, vol.19, pp.9-42, 2016.

M. Procter, T. M. Suter, E. De-azambuja, U. Dafni, V. Van-dooren et al., Longer-term 467 assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) 468 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, pp.3422-3428, 2010.

M. J. Piccart-gebhart, M. Procter, B. Leyland-jones, A. Goldhirsch, M. Untch et al., 470 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, vol.471, pp.1659-1672, 2005.

H. L. Mcarthur and S. Chia, Cardiotoxicity of trastuzumab in clinical practice, N Engl J Med, vol.473, pp.94-95, 2007.

B. Chen, X. Peng, L. Pentassuglia, C. C. Lim, and D. B. Sawyer, Molecular and cellular mechanisms of 475 anthracycline cardiotoxicity, Cardiovasc Toxicol, vol.7, pp.114-121, 2007.

T. Sim?nek, M. Stérba, O. Popelová, M. Adamcová, R. Hrdina et al., Anthracycline-induced 477 cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol Rep PR, vol.478, pp.154-171, 2009.

K. B. Wallace, Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

, Cardiovasc Toxicol, vol.7, pp.101-107, 2007.

W. Zhu, M. H. Soonpaa, H. Chen, W. Shen, R. M. Payne et al., Acute doxorubicin 482 cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin 483 pathway, Circulation, vol.119, pp.99-106, 2009.

D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich et al., Human breast cancer: 485 correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.486, pp.177-182, 1987.

M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl et al., Multinational 488 study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who 489 have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy 490 for metastatic disease, J Clin Oncol Off J Am Soc Clin Oncol, vol.17, pp.2639-2648, 1999.

J. Baselga, X. Carbonell, N. Castañeda-soto, M. Clemens, M. Green et al., Phase II study 492 of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-493 weekly schedule, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.2162-2171, 2005.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of 495 chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that 496 overexpresses HER2, N Engl J Med, vol.344, pp.783-792, 2001.

M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac et al., Randomized 498 phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with 499 human epidermal growth factor receptor 2-positive metastatic breast cancer administered as 500 first-line treatment: the M77001 study group, J Clin Oncol Off J Am Soc Clin Oncol, vol.501, pp.4265-4274, 2005.

M. Cuello, S. A. Ettenberg, A. S. Clark, M. M. Keane, R. H. Posner et al., Down-regulation of 503 the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related 504 apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that 505 overexpress erbB-2, Cancer Res, vol.61, pp.4892-4900, 2001.

E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer et al., Trastuzumab plus 507 adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, vol.508, pp.1673-1684, 2005.

P. P. Sengupta, D. W. Northfelt, F. Gentile, J. L. Zamorano, and B. K. Khandheria, Trastuzumab-induced 510 cardiotoxicity: heart failure at the crossroads, Mayo Clin Proc, vol.83, pp.197-203, 2008.

A. Farolfi, E. Melegari, M. Aquilina, E. Scarpi, T. Ibrahim et al., Trastuzumab-induced 512 cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and 513 protective factors, Heart Br Card Soc, vol.99, pp.634-639, 2013.

G. Fried, T. Regev, and M. Moskovitz, Trastuzumab-related cardiac events in the treatment of early 515 breast cancer, Breast Cancer Res Treat, vol.142, pp.1-7, 2013.

P. Thavendiranathan, H. Abdel-qadir, H. D. Fischer, X. Camacho, E. Amir et al., Breast 517 Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical 518 Practice: A Population-Based Cohort Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.34, pp.2239-519, 2016.

L. Moja, L. Tagliabue, S. Balduzzi, E. Parmelli, V. Pistotti et al., Trastuzumab containing 521 regimens for early breast cancer, Cochrane Database Syst Rev, vol.006243, 2012.

A. Albini, E. Cesana, F. Donatelli, R. Cammarota, E. O. Bucci et al., Cardio-oncology in 523 targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors, Future Cardiol, vol.7, pp.693-704, 2011.

N. L. Spector, Y. Yarden, B. Smith, L. Lyass, P. Trusk et al., Activation of AMP-activated protein 526 kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

, Proc Natl Acad Sci U S A, vol.104, pp.10607-10612, 2007.

S. J. Fuller, K. Sivarajah, and P. H. Sugden, ErbB receptors, their ligands, and the consequences of their 529 activation and inhibition in the myocardium, J Mol Cell Cardiol, vol.44, pp.831-854, 2008.

Y. Y. Zhao, D. R. Sawyer, R. R. Baliga, D. J. Opel, X. Han et al., Neuregulins promote 531 survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal 532 and adult ventricular myocytes, J Biol Chem, vol.273, pp.10261-10269, 1998.

R. Iwamoto, S. Yamazaki, M. Asakura, S. Takashima, H. Hasuwa et al.,

, EGF-like growth factor and ErbB signaling is essential for heart function, Proc Natl Acad Sci, vol.100, pp.3221-3226, 2003.

G. W. De-keulenaer, K. Doggen, and K. Lemmens, The vulnerability of the heart as a pluricellular 537 paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer 538 therapy, Circ Res, vol.106, pp.35-46, 2010.

G. M. Cote, D. B. Sawyer, and B. A. Chabner, ERBB2 inhibition and heart failure, N Engl J Med, vol.540, p.876, 2013.

A. Seidman, C. Hudis, M. K. Pierri, S. Shak, V. Paton et al., Cardiac dysfunction in the 542 trastuzumab clinical trials experience, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, pp.1215-1221, 2002.

I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray, Trastuzumab in the adjuvant 544 treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized 545 controlled trials, The Oncologist, vol.13, pp.620-630, 2008.

E. Bowles, R. Wellman, H. S. Feigelson, A. A. Onitilo, A. N. Freedman et al., Risk of heart 547 failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective 548 cohort study, J Natl Cancer Inst, vol.104, pp.1293-1305, 2012.

A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu et al., Pertuzumab plus trastuzumab 550 in combination with standard neoadjuvant anthracycline-containing and anthracycline-free 551 chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized 552 phase II cardiac safety study (TRYPHAENA), Ann Oncol Off J Eur Soc Med Oncol, vol.24, pp.2278-553, 2013.

M. Sendur, S. Aksoy, and K. Altundag, Cardiotoxicity of novel HER2-targeted therapies, Curr Med 555 Res Opin, vol.29, pp.1015-1024, 2013.

C. M. Schneider, C. C. Hsieh, L. K. Sprod, S. D. Carter, and R. Hayward, Effects of supervised exercise training 557 on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment, Cancer, vol.110, pp.918-925, 2007.

A. S. Fairey, K. S. Courneya, C. J. Field, G. J. Bell, L. W. Jones et al., Effects of exercise training on 560 fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor 561 binding proteins in postmenopausal breast cancer survivors

, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.563, pp.721-727, 2003.

T. Cornette, F. Vincent, S. Mandigout, M. T. Antonini, S. Leobon et al., Effects of home-565 based exercise training on VO2 in breast cancer patients under adjuvant or neoadjuvant 566 chemotherapy (SAPA): a randomized controlled trial, Eur J Phys Rehabil Med, vol.52, pp.223-232, 2016.

V. De-luca, C. Minganti, P. Borrione, E. Grazioli, C. Cerulli et al., Effects of concurrent 568 aerobic and strength training on breast cancer survivors: a pilot study, Public Health, vol.569, pp.126-132, 2016.

W. E. Hornsby, P. S. Douglas, M. J. West, A. A. Kenjale, A. R. Lane et al., Safety and efficacy 571 of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a 572 phase II randomized trial, Acta Oncol Stockh Swed, vol.53, pp.65-74, 2014.

C. M. Dieli-conwright, K. S. Courneya, W. Demark-wahnefried, N. Sami, K. Lee et al., Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in 575 overweight and obese breast cancer survivors: a randomized controlled trial, Breast Cancer Res 576 BCR, vol.20, p.124, 2018.

A. Foucaut, S. E. Berthouze-aranda, M. Touillaud, A. Kempf-lépine, C. Baudinet et al., Reduction of health risk factors through an adapted physical activity program in patients 579 with breast cancer, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.580, pp.1097-1104, 2014.

C. Kim, D. Kang, B. A. Smith, and K. A. Landers, Cardiopulmonary responses and adherence to 582 exercise in women newly diagnosed with breast cancer undergoing adjuvant therapy, Cancer, vol.583, pp.156-165, 2006.

G. G. Kolden, T. J. Strauman, A. Ward, J. Kuta, T. E. Woods et al., A pilot study of group 585 exercise training (GET) for women with primary breast cancer: feasibility and health benefits, Psychooncology, vol.11, pp.447-456, 2002.

H. J. Leach, J. M. Danyluk, and K. C. Nishimura, Culos-Reed SN: Benefits of 24 versus 12 weeks of exercise 588 and wellness programming for women undergoing treatment for breast cancer. Support Care 589 Cancer Off, J Multinatl Assoc Support Care Cancer, vol.24, pp.4597-4606, 2016.

M. Noble, C. Russell, L. Kraemer, and M. Sharratt, UW WELL-FIT: the impact of supervised exercise 591 programs on physical capacity and quality of life in individuals receiving treatment for cancer

, Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.20, pp.865-873, 2012.

K. M. Sturgeon, B. Ky, J. R. Libonati, and K. H. Schmitz, The effects of exercise on cardiovascular outcomes 594 before, during, and after treatment for breast cancer, Breast Cancer Res Treat, vol.143, pp.219-595, 2014.

L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey, Early Breast Cancer Therapy and 597 Cardiovascular Injury, J Am Coll Cardiol, vol.50, pp.1435-1441, 2007.

A. N. Kavazis, J. M. Mcclung, D. A. Hood, and S. K. Powers, Exercise induces a cardiac mitochondrial 599 phenotype that resists apoptotic stimuli, Am J Physiol Heart Circ Physiol, vol.294, pp.928-935, 2008.

A. Ascensão, R. Ferreira, and J. Magalhães, Exercise-induced cardioprotection--biochemical, 601 morphological and functional evidence in whole tissue and isolated mitochondria, Int J Cardiol, vol.602, pp.16-30, 2007.

L. W. Jones, L. A. Habel, E. Weltzien, A. Castillo, D. Gupta et al., , p.604

, Cardiovascular Events in Women With Nonmetastatic Breast Cancer, J Clin Oncol Off J Am Soc, vol.34, pp.2743-2749, 2016.

M. J. Haykowsky, J. R. Mackey, R. B. Thompson, L. W. Jones, and D. I. Paterson, Adjuvant Trastuzumab 607 Induces Ventricular Remodeling Despite Aerobic Exercise Training, Clin Cancer Res, vol.608, pp.4963-4967, 2009.

K. S. Courneya, R. J. Segal, J. R. Mackey, K. Gelmon, R. D. Reid et al., Effects of aerobic 610 and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a 611 multicenter randomized controlled trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, pp.4396-612, 2007.

N. Travier, M. J. Velthuis, S. Bisschop, C. N. Van-den-buijs, B. Monninkhof et al., 614 Effects of an 18-week exercise programme started early during breast cancer treatment: a 615 randomised controlled trial, BMC Med, vol.13, p.121, 2015.

K. S. Courneya, D. C. Mckenzie, J. R. Mackey, K. Gelmon, C. M. Friedenreich et al., Subgroup 617 effects in a randomised trial of different types and doses of exercise during breast cancer 618 chemotherapy, Br J Cancer, vol.111, pp.1718-1725, 2014.

Q. Jacquinot, N. Meneveau, M. Chatot, F. Bonnetain, B. Degano et al., A phase 2 620 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 621 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment 622 by trastuzumab: design of the CARDAPAC study, BMC Cancer, vol.17, p.425, 2017.

A. Ginzac, T. Émilie, M. Pascale, D. Isabelle, V. P. Judith et al., Weight evolution 624 during endocrine therapy for breast cancer in postmenopausal patients: impact of initial fat 625 mass percentage and previous adjuvant treatments, Clin Breast Cancer

S. Battisti, F. M. Guida, F. Coppa, D. M. Vaccaro, D. Santini et al., Modification of abdominal 628 fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D 629 computed tomography volumetry, Clin Breast Cancer, vol.14, pp.365-370, 2014.

J. Zhu, L. Ebert, X. Liu, and S. Chan, A mobile application of breast cancer e-support program 631 versus routine Care in the treatment of Chinese women with breast cancer undergoing 632 chemotherapy: study protocol for a randomized controlled trial, BMC Cancer, vol.17, p.291, 2017.

S. S. Coughlin, G. M. Besenyi, D. Bowen, D. Leo, and G. , Development of the Physical activity and Your 634 Nutrition for Cancer (PYNC) smartphone app for preventing breast cancer in women, vol.635, p.5, 2017.

I. Y. Cheong, A. Sy, W. C. Cha, M. Y. Rha, S. T. Kim et al., Efficacy of Mobile Health Care 637 Application and Wearable Device in Improvement of Physical Performance in Colorectal Cancer 638 Patients Undergoing Chemotherapy, Clin Colorectal Cancer, vol.17, pp.353-362, 2018.

K. S. Courneya, D. C. Mckenzie, R. D. Reid, J. R. Mackey, K. Gelmon et al., Barriers to 640 supervised exercise training in a randomized controlled trial of breast cancer patients receiving 641 chemotherapy, Ann Behav Med Publ Soc Behav Med, vol.35, pp.116-122, 2008.

A. Henriksson, C. Arving, B. Johansson, H. Igelström, and K. Nordin, Perceived barriers to and 643 facilitators of being physically active during adjuvant cancer treatment, Patient Educ Couns, vol.644, pp.1220-1226, 2016.

A. Husebø, B. Karlsen, H. Allan, J. A. Søreide, and E. Bru, Factors perceived to influence exercise 646 adherence in women with breast cancer participating in an exercise programme during 647 adjuvant chemotherapy: a focus group study, J Clin Nurs, vol.24, pp.500-510, 2015.

C. Emslie, F. Whyte, A. Campbell, N. Mutrie, L. Lee et al., I wouldn't have been 649 interested in just sitting round a table talking about cancer"; exploring the experiences of 650 women with breast cancer in a group exercise trial, Health Educ Res, vol.22, pp.827-838, 2007.

A. Wurz, A. St-aubin, and J. Brunet, Breast cancer survivors' barriers and motives for participating in a 652 group-based physical activity program offered in the community, Support Care Cancer Off J, vol.653

, Multinatl Assoc Support Care Cancer, vol.23, pp.2407-2416, 2015.

K. Hefferon, H. Murphy, J. Mcleod, N. Mutrie, and A. Campbell, Understanding barriers to exercise 655 implementation 5-year post-breast cancer diagnosis: a large-scale qualitative study. Health 656, Educ Res, vol.28, pp.843-856, 2013.

S. Y. Loh, S. Y. Lee, K. F. Quek, and L. Murray, Barriers to participation in a randomized controlled trial of 658 Qigong exercises amongst cancer survivors: lessons learnt, Asian Pac J Cancer Prev APJCP, vol.659, pp.6337-6342, 2012.

C. Charlier, E. Van-hoof, E. Pauwels, L. Lechner, and H. Spittaels, De Bourdeaudhuij I: The contribution 661 of general and cancer-related variables in explaining physical activity in a breast cancer 662 population 3 weeks to 6 months post-treatment, Psychooncology, vol.22, pp.203-211, 2013.

S. Y. Loh, S. Chew, and S. Lee, Barriers to exercise: perspectives from multiethnic cancer survivors 664 in Malaysia, Asian Pac J Cancer Prev APJCP, vol.12, pp.1483-1488, 2011.

A. J. Ottenbacher, R. S. Day, W. C. Taylor, S. V. Sharma, R. Sloane et al., Exercise among 666 breast and prostate cancer survivors--what are their barriers?, J Cancer Surviv Res Pract, vol.667, pp.413-419, 2011.

L. Steinhilper, S. Geyer, and S. Sperlich, Health behavior change among breast cancer patients, Int J 669 Public Health, vol.58, pp.603-613, 2013.

L. Q. Rogers, C. Matevey, P. Hopkins-price, P. Shah, G. Dunnington et al., Exploring social 671 cognitive theory constructs for promoting exercise among breast cancer patients, Cancer Nurs, vol.672, pp.462-473, 2004.

M. Browall, S. Mijwel, H. Rundqvist, and Y. Wengström, Physical Activity During and After Adjuvant 674 Treatment for Breast Cancer: An Integrative Review of Women's Experiences, Integr Cancer 675 Ther, vol.17, pp.16-30, 2018.

F. M. Perna, L. Craft, C. S. Carver, and M. H. Antoni, Negative affect and barriers to exercise among early 677 stage breast cancer patients, Health Psychol Off J Div Health Psychol Am Psychol Assoc, vol.678, pp.275-279, 2008.

L. W. Jones, K. S. Courneya, A. S. Fairey, and J. R. Mackey, Effects of an oncologist's recommendation to 680 exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a 681 single-blind, randomized controlled trial, Ann Behav Med Publ Soc Behav Med, vol.28, pp.105-682, 2004.

C. Lanhers, M. Duclos, A. Guttmann, E. Coudeyre, B. Pereira et al., General Practitioners' 684 Barriers to Prescribe Physical Activity: The Dark Side of the Cluster Effects on the Physical 685 Activity of Their Type 2 Diabetes Patients, PloS One, vol.10, p.140429, 2015.

M. Duclos, S. Dejager, N. Postel-vinay, S. Di-nicola, S. Quéré et al., Physical activity in patients 687 with type 2 diabetes and hypertension--insights into motivations and barriers from the MOBILE 688 study, Vasc Health Risk Manag, vol.11, pp.361-371, 2015.

W. Demark-wahnefried, E. C. Clipp, I. M. Lipkus, D. Lobach, D. C. Snyder et al., Main 690 Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print 691 Intervention Among Breast and Prostate Cancer Survivors, J Clin Oncol, vol.25, pp.2709-2718, 2007.

B. M. Pinto, G. M. Frierson, C. Rabin, J. J. Trunzo, and B. H. Marcus, Home-based physical activity 693 intervention for breast cancer patients, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.3577-694, 2005.

W. Demark-wahnefried, M. C. Morey, E. C. Clipp, C. F. Pieper, D. C. Snyder et al., Leading the 696 Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast 697 and prostate cancer survivors, Control Clin Trials, vol.24, pp.206-223, 2003.

C. Rabin, N. Simpson, K. Morrow, and B. Pinto, Behavioral and psychosocial program needs of young 699 adult cancer survivors, Qual Health Res, vol.21, pp.796-806, 2011.

A. D. Goode, S. P. Lawler, C. L. Brakenridge, M. M. Reeves, and E. G. Eakin, Telephone, print, and Web-based 701 interventions for physical activity, diet, and weight control among cancer survivors: a 702 systematic review, J Cancer Surviv Res Pract, vol.9, pp.660-682, 2015.

A. Hatchett, J. S. Hallam, and M. A. Ford, Evaluation of a social cognitive theory-based email 704 intervention designed to influence the physical activity of survivors of breast cancer, Psychooncology, vol.22, pp.829-836, 2013.

, Table 1: Physical activity interventions reporting cardiopulmonary outcomes among breast cancer 710 patients during and after treatment

, Adj: Adjuvant; AET: aerobic exercise training; CT: chemotherapy; Ctrl: Control; HR max : maximum 712 heart rate; HT: Hormone therapy; NA: Not applicable; NACT: Neoadjuvant chemotherapy; ND: Not 713 done; RCT: Radiochemotherapy; RET: Resistance exercise training; RM: repetition maximum; RPE: 714 Rate of perceived exertion